The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...

After announcing a phase 3 launch based on positive midstage results, iTeos and GSK are finally sharing the highlights from ...

Find out all you need to know about bispecific antibodies, including how they work and what the current clinical landscape ...

The published belrestotug/dostarlimab data is still too immature to prove the combination’s capability to disrupt the NSCLC ...

The combination of belrestotug and dostarlimab significantly improved response rates in patients with previously untreated ...

High response rates reported by GSK and iTeos at the 2024 European Society for Medical Oncology Congress offer a ray of light ...

More than two years after an initial FDA approval in melanoma, Bristol Myers Squibb is moving its PD-1/LAG-3 combo Opdualag ...

Phase III data presented at the WCLC suggests the new VEGF and PD-L1 inhibitor could prolong progression-free survival versus Merck's anti-PD-1 blockbuster.

Head-to-Head Phase 3 Trial Compared to Pembrolizumab Initiated HONG KONG, Sept. 15, 2024 /PRNewswire/ — At the 2024 European ...

在化疗和靶向治疗时代，化疗不敏感，基因突变较少，晚期肝细胞癌（HCC）系统治疗进展十分缓慢。在ICIs治疗时代，晚期HCC系统治疗方案层出不穷。基于已经成熟的得到验证的靶点进行药物之间 ...

As a numerical comparison, Keytruda monotherapy achieved a 45% ORR in first-line PD-L1 high patients ... drug conjugates and bispecific antibodies. "ESMO 2024: TIGIT race tightens with first ...